NAARDEN, The Netherlands and MIAMI, Nov. 03, 2026 (GLOBE NEWSWIRE) — NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that company management will participate in the following upcoming investor conferences:

  • Guggenheim 3rd Annual Healthcare Innovation Conference in Boston, MA on Tuesday, November 10, 2026. Ian Somaiya, Chief Financial Officer, and Matthew Philippe, Executive Vice President, Head of Investor Relations, will participate in a fireside chat at 4:00 p.m. ET on Tuesday, November 10.
  • Stifel 2026 Healthcare Conference in New York, NY on Wednesday, November 11, 2026. Michael Davidson, M.D., Chief Executive Officer, Ian Somaiya, Chief Financial Officer, and Matthew Philippe, Executive Vice President, Head of Investor Relations, will participate in a fireside chat at 11:20 a.m. ET on Wednesday, November 11.
  • Jefferies Global Healthcare Conference in London, UK on Wednesday, November 18, 2026. John Kastelein, M.D., Ph.D., FESC, Founder and Chief Scientific Officer, Ian Somaiya, Chief Financial Officer, and Matthew Philippe, Executive Vice President, Head of Investor Relations, will participate in a fireside chat at 11:30 a.m. GMT on Wednesday, November 18.

Live webcasts of the fireside chats will be available through the investor relations section of the NewAmsterdam Pharma website at ir.newamsterdampharma.com. Following the live webcasts, archived replays will be available on the Company’s website.

About NewAmsterdam

NewAmsterdam Pharma (Nasdaq: NAMS) is a late-stage biopharmaceutical company dedicated to building a new standard of care for people living with cardiometabolic and neurodegenerative diseases. The Company is advancing therapies designed to address a significant unmet need for safe, well-tolerated, and convenient treatment options that lower LDL-C while advancing innovation beyond a single marker to better address cardiovascular risk. In multiple Phase 3 trials, NewAmsterdam is investigating obicetrapib, an oral, low-dose, once-daily CETP inhibitor, alone and as a fixed-dose combination with ezetimibe, in patients at risk of cardiovascular disease with elevated LDL-C. Guided by its mission, the Company challenges convention with courage, translates deep biological insight into meaningful patient impact, and delivers with rigor, precision, and purpose.

Company Contact
Matthew Philippe
P: 1-917-882-7512
matthew.philippe@newamsterdampharma.com

Media Contact
Real Chemistry on behalf of NewAmsterdam
Christian Edgington
P: 1-513-310-6410
cedgington@realchemistry.com

Investor Contact
Precision AQ on behalf of NewAmsterdam
Austin Murtagh
P: 1-212-698-8696
austin.murtagh@precisionaq.com

PRINCETON, N.J., Nov. 03, 2026 (GLOBE NEWSWIRE) — UroGen Pharma Ltd. (Nasdaq: URGN), a biotechnology company focused on transforming the treatment of urothelial and specialty cancers, today announced that management will present at the Guggenheim Securities 3rd Annual Healthcare Innovation Conference, to take place November 9-11, 2026.

Presentation Details

Date / Time: November 10, 2026, at 11:30 AM ET
Format: Fireside chat and 1×1 investor meetings
Location: Boston, MA
Webcast Link: here
   

The webcast from the conference will also be available on UroGen’s corporate website, under Events & Presentations. A replay will be available for approximately 90 days.

About UroGen Pharma Ltd.

UroGen is a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers because patients deserve better options. UroGen has developed RTGel reverse-thermal hydrogel, a proprietary sustained-release, hydrogel-based platform technology that has the potential to improve the therapeutic profiles of existing drugs. UroGen’s sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. UroGen’s first product is approved to treat low-grade upper tract urothelial cancer, and UroGen’s second product is approved for adult patients with recurrent low-grade intermediate-risk non-muscle-invasive bladder cancer. Both products are designed to ablate tumors by non-surgical means. UroGen is headquartered in Princeton, NJ with operations in Israel.

Visit www.urogen.com to learn more or follow us on X, @UroGenPharma.

INVESTORS:

Vincent Perrone
Senior Director, Investor Relations
vincent.perrone@urogen.com
609-460-3588 ext. 1093

MEDIA:

Cindy Romano
Director, Corporate Communications
cindy.romano@urogen.com
609-460-3566 ext. 1083

SOUTH SAN FRANCISCO, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) — Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced that management will participate in the following investor conferences before the end of 2026:

Guggenheim 3rd Annual Healthcare Innovation Conference – Boston
Fireside chat on Tuesday, November 10, 2026, at 10:00 a.m. ET

Stifel 2026 Healthcare Conference – New York
Fireside chat on Wednesday, November 11, 2026, at 1:20 p.m. ET

UBS Global Biopharma Conference – London
Fireside chat on Monday, November 16, 2026, at 2:00 p.m. GMT

9th Annual Evercore Healthcare Conference – Miami
Fireside chat on Tuesday, December 1, 2026, at 7:55 a.m. ET

A live webcast of each presentation will be available in the investors section of the company’s website at www.septerna.com. The webcasts will be archived for at least 30 days following the presentation.

About Septerna
Septerna, Inc. is a clinical-stage biotechnology company with a world-class team of GPCR experts and drug developers advancing cutting-edge science to unlock the full potential of GPCR therapies for patients with significant unmet needs. The company’s proprietary Native Complex Platform® is designed to enable new approaches to GPCR drug discovery and has led to the development of a diverse pipeline of novel oral small molecule drug candidates. Septerna is advancing programs in endocrinology, immunology and inflammation, metabolic diseases and additional therapeutic areas, both independently and with partners. For more information, please visit www.septerna.com.

Investor Contact:
Renee Leck, THRUST
renee@thrustsc.com

Media Contact:
Carly Scaduto, THRUST
carly@thrustsc.com

Project will integrate solar, battery storage, and on-site generation to strengthen mission readiness amid grid outages and other disruptions

Army Corp project image

LOUISVILLE, Ky. and NEW YORK, Nov. 03, 2026 (GLOBE NEWSWIRE) — ABM (NYSE: ABM), a leading provider of facility, engineering, and infrastructure solutions, in coordination with joint venture partner AACON General Contractors, today announced that AACON-RavenVolt JV, LLC has been awarded a construction contract by the U.S. Army Corps of Engineers (USACE) Louisville District to construct an advanced microgrid at White Sands Missile Range in New Mexico. RavenVolt is ABM’s energy solutions subsidiary.

Awarded under the Department of Defense’s Energy Resilience and Conservation Investment Program (ERCIP), the project will combine solar power, battery energy storage, on-site backup generation, and advanced controls to safeguard mission-critical military operations against external grid outages, extreme weather events, and other power disruptions.

“Reliable power is fundamental to mission readiness, and critical military installations require robust, modern infrastructure to guarantee continuous operation,” said Mark Hawkinson, President, Engineering & Infrastructure Solutions, ABM. “Through the combined strengths of AACON General Contractors and RavenVolt, the AACON-RavenVolt joint venture is proud to partner with the U.S. Army Corps of Engineers Louisville District to deliver a resilient power system engineered to sustain White Sands Missile Range when the commercial grid cannot.”

Constructed under a Design-Bid-Build framework, the secure feeder-level microgrid will integrate a carport-mounted solar photovoltaic (PV) array, a high-capacity battery energy storage system (BESS), dispatchable on-site generators, and an intelligent microgrid control system. Working as a single, coordinated system, these distributed energy assets will allow the installation to seamlessly island, reduce dependence on the local utility grid, and provide redundant power to vital cantonment area facilities. The scope also includes new electrical distribution lines, fiber optic communications, and security infrastructure.

The White Sands Missile Range award demonstrates AACON-RavenVolt JV, LLC’s specialized capability in delivering complex federal energy resilience and mission-critical infrastructure projects.

About AACON-RavenVolt JV, LLC
AACON-RavenVolt JV, LLC is a Small Business joint venture combining the federal general contracting experience of AACON General Contractors (Louisville, KY) with the turnkey microgrid and distributed energy engineering expertise of RavenVolt, a subsidiary of ABM. The partnership provides federal agencies with dependable, end-to-end energy resilience and infrastructure construction capabilities.

About ABM
ABM (NYSE: ABM) is one of the world’s largest providers of integrated facility, engineering, and infrastructure solutions. Every day, our over 100,000 team members deliver essential services that make spaces cleaner, safer, and more efficient, enhancing the overall occupant experience. ABM serves a wide range of market sectors including commercial real estate, aviation, mission critical, and manufacturing and distribution. With over $8 billion in annual revenue and a blue-chip client base, ABM delivers innovative technologies and sustainable solutions that enhance facilities and empower clients to achieve their goals. Committed to creating smarter, more connected spaces, ABM is investing in the future to meet evolving challenges and build a healthier, thriving world. ABM: Driving possibility, together.

For more information, visit www.abm.com.

MEDIA CONTACT: 
Michael Valentino 
ABM 
media@abm.com  

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/e071d9b9-a270-48ff-9558-b0655193742c

Board of Directors authorizes repurchase of up to $30 million of the Company’s common stock

LOS ANGELES, Nov. 03, 2026 (GLOBE NEWSWIRE) — XMax Inc. (NASDAQ: XMAX) (“XMax” or the “Company”), a distributor of contemporary furniture and artificial intelligence software and platform-based service provider, today announced that its Board of Directors has authorized a share repurchase program under which the Company may repurchase up to $30 million in aggregate purchase price of its outstanding common stock, par value $0.001 per share. Shares may be repurchased only at prices below $5.50 per share.

The program will begin on a date to be determined (the “Commencement Date”) after the Company has (i) publicly released its financial results for the fiscal quarter ended September 30, 2026 by press release (“Earnings Release”), (ii) publicly disclosed any material nonpublic information, and (iii) engaged a broker-dealer for the program. No repurchases will be made before the Commencement Date, and the program will expire three months after it.

Repurchases are expected to be made from time to time through open-market purchases, which may include purchases under a trading plan intended to satisfy Rule 10b5-1 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and are intended to be made in accordance with Rule 10b-18 under the Exchange Act and other applicable legal requirements.

The timing, manner, price (subject to the $5.50 per share limit) and amount of any repurchases will be determined by the Company’s management based on its evaluation of market conditions, the trading price of the Company’s common stock, liquidity and capital requirements, legal requirements, and other factors. The program does not obligate the Company to repurchase any particular number of shares, and it may be suspended, modified, or discontinued at any time without prior notice. The Company expects to fund repurchases with its existing cash and cash equivalents.

“The Board’s authorization of this share repurchase program reflects our confidence in XMax’s long-term strategy and our commitment to creating value for shareholders,” said Andy Lu, Chief Executive Officer of XMax. “As we continue to develop our artificial intelligence software and platform-based services alongside our contemporary furniture business, we intend to take a disciplined approach to capital allocation, balancing investment in the growth of the business with returns to our shareholders.”

About XMax Inc.

Headquartered in Commerce, California, XMax Inc. (NASDAQ: XMAX), formerly known as Nova LifeStyle, Inc., is a diversified company engaged in the design, sourcing, and distribution of contemporary furniture, as well as the development of artificial intelligence technologies and applications. The Company operates through an established global network of suppliers, distributors, and e-commerce channels, serving a broad customer base. The Company has expanded into artificial intelligence technologies, including AI software and platform-based services through its wholly owned subsidiaries XMax AI Inc. and Elonx AI Holdings PTE. LTD., to support future growth. By leveraging emerging technologies, the Company aims to drive diversification and long-term value creation.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements include, but are not limited to, statements regarding the share repurchase program, the expected timing of its commencement and of the Earnings Release, and the manner, timing, amount and funding of any repurchases. These statements are based on current expectations, assumptions and analyses made by us in light of our experience and our perception of trends, current conditions and expected future developments, as well as other factors we believe are appropriate in the circumstances, and are subject to risks and uncertainties that may cause actual results to differ materially, including changes in the trading price of the Company’s common stock, market conditions, the Company’s financial condition, liquidity and capital requirements, legal and regulatory requirements, and the other risks described in the Company’s filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q. All statements other than statements of historical fact are, or may be deemed to be, forward-looking statements. In some cases, forward-looking statements can be identified by the use of forward-looking terms such as “anticipate,” “estimate,” “believe,” “continue,” “could,” “intend,” “may,” “plan,” “potential,” “predict,” “should,” “will,” “expect,” “objective,” “projection,” “forecast,” “goal,” “guidance,” “outlook,” “effort,” “target,” “trajectory,” “focus,” “work to,” “attempt,” “pursue,” or the negative of these terms or other comparable terms. However, the absence of these words does not mean that the statements are not forward-looking. XMax Inc. undertakes no obligation to update any forward-looking statements except as required by law.

Investor Relations Contact

ICR LLC
XMaxIR@icrinc.com

Nuclear News’ recognition highlights Waples’ technical leadership and contributions to advancing innovative nuclear waste disposal solutions

PLANO, Texas, Nov. 03, 2026 (GLOBE NEWSWIRE) — Deep Isolation Nuclear, Inc. (OTCQB: DBHL) (“Deep Isolation” or the “Company”), a leading innovator in nuclear waste disposal technology, today announced that Matt Waples, the Company’s Director of Engineering, has been named to Nuclear News’ 2026 “40 Under 40” list, recognizing emerging leaders whose technical expertise and innovation are helping shape the future of the nuclear industry. Published by the American Nuclear Society, Nuclear News’ annual “40 Under 40” program celebrates young professionals making meaningful contributions to nuclear science, technology, and industry advancement.

“Matt exemplifies the technical excellence and leadership needed to address one of the nuclear industry’s most important challenges,” said Rod Baltzer, CEO of Deep Isolation. “His ability to translate complex engineering challenges into practical solutions has been instrumental to our progress. We are incredibly proud to see his contributions recognized among the next generation of nuclear industry leaders.”

“It is an honor to be recognized alongside so many talented professionals working to advance nuclear energy,” said Waples. “Developing practical solutions for nuclear waste disposal requires collaboration, rigorous engineering and a commitment to long-term safety. I am proud to be part of a team helping move these technologies toward real-world application.”

Since joining Deep Isolation in 2022, Matt Waples has played a central role in advancing the Company’s deep borehole disposal technology, bringing expertise across engineering design, regulatory analysis, safety, operations and project management. His contributions have supported key research and development initiatives aimed at establishing practical, scalable pathways for the long-term disposal of spent nuclear fuel and high-level radioactive waste.

Waples played a key role in Deep Isolation’s U.S. Department of Energy-funded ARPA-E UPWARDS project, leading regulatory analysis and waste acceptance criteria development. His leadership extends to the ARPA-E SAVANT project, where his work on disposal canister materials and supply chains contributed to a paper receiving a “Superior” recognition at the 2025 Waste Management Symposia. Waples has also supported international initiatives and collaborative research through the International Atomic Energy Agency and the OECD Nuclear Energy Agency’s WISARD project.

About Deep Isolation

Deep Isolation (OTCQB: DBHL) is the first company to undertake development of technologies for nuclear waste disposal in deep boreholes. Deep Isolation’s solution is designed to offer a unique approach to help countries identify, plan for and complete the necessary steps to dispose of their nuclear waste inventories. With over 100 patents issued to date, Deep Isolation’s technology is designed to leverage proven drilling practices to allow safe isolation of waste deep underground in horizontal, vertical, or slanted borehole repositories. Deep Isolation’s Universal Canister System is engineered to support integrated management of spent fuel and high-level radioactive waste from legacy and advanced reactors across storage, transportation, and eventual disposal. In January 2026, Deep Isolation launched a full-scale, at-depth deep borehole Commercialization Pilot for its solution at Cameron, Texas, in collaboration with the Deep Borehole Demonstration Center, Halliburton (NYSE: HAL), Amentum (NYSE: AMTM), NAC International (TYO: 7004), and Occlusion Nuclear Solutions.

For more information, visit: https://www.deepisolation.com

Media Contact
Sophie McCallum
media@deepisolation.com

Investor Contact
Caldwell Bailey
InvestorRelations@deepisolation.com

Forward-Looking Statements

Statements contained in this news release that are not historical facts are “forward-looking information” or “forward-looking statements” (collectively, “forward-looking statements”) within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include, but are not limited to, statements regarding our plans, objectives and expectations for our business, the future growth of our business and the nuclear energy and nuclear waste disposal industries as a whole, and future benefits expected to arise from our strategic partnerships. In certain cases, forward-looking statements can be identified by the use of words and phrases or variations of words and phrases or statements such as “may,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “will,” “could,” “project,” “target,” “potential,” “continue” and similar expressions. Forward-looking statements are based on management’s belief and assumptions, including current expectations and projections about future events and trends, and on information currently available to management.

Forward-looking statements in this or any other news release are subject to a number of risks, uncertainties, and assumptions that could cause actual results to be materially different from those expressed or implied by such forward-looking statements. Such risks, uncertainties, and assumptions are subject to a number of factors, including, among others: the failure of a market to develop for our deep borehole disposal solutions as quickly as we expect or at all; a failure of demand for our solution to develop sufficiently; regulatory and legal developments, including issues relating to obtaining regulatory approvals or permissions on the timelines we expect or at all; our lack of profitability; delays or failure in our initiative to complete a full-scale, at-depth demonstration of our Universal Canister System and our deep borehole solution; our failure to enter into contracts with customers or, once we do enter into contracts, to continue such contractual relationships or to receive new contract awards; our dependency on governmental contracts and awards; our failure to manage our growth effectively or to execute our business plan; a failure to sustain and expand relationships with governmental entities and strategic partners; failure in the assumptions or analyses we have used in supporting forecasts or plans; our inability to commercialize our products at scale; the development or deployment of other technologies or solutions supplanting or competing with our technologies; challenges to our intellectual property; failures to protect, maintain, enforce, and enhance our intellectual property, and claims by others of intellectual property infringement; political and public perceptions of nuclear energy, including perceptions as to accidents or other high-profile events involving nuclear power facilities or radioactive materials; our liquidity and ability to raise capital; any inability to control operating and project costs and project delays or other project-related problems; security (including cybersecurity) breaches or disruptions; geopolitical, macroeconomic, domestic events or crises, including supply chain disruptions and other risks and uncertainties outside of our control; weather and effects of climate change; and litigation or legal proceedings that may be brought against us.

The foregoing is not an exhaustive list of all the factors that may cause any forward-looking statements to prove inaccurate or our actual results to differ materially from our expectations and forecasts. Moreover, we operate in a highly regulated environment. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties, and assumptions, the future events and trends discussed in this release may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements, and we cannot guarantee future results, performance, or achievements. Accordingly, readers should not place undue reliance on forward-looking statements. We undertake no obligation to update any forward-looking statements for any reason after the date of this release or to conform these statements to actual results or revised expectations, except as required by law. ”

Additional information concerning the factors above and other factors can be found in the Company’s public filings with the Securities and Exchange Commission (the “SEC”), including the sections titled “Forward-Looking Statements” and “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025 filed with the SEC on March 30, 2026, subsequent quarterly reports on Form 10-Q filed with the SEC, our Form S-1, originally filed August 18, 2025 and subsequently amended, our Proxy Statement for our 2026 Annual Meeting as filed on April 29, 2026, and in filings with the SEC that will be made in the future. The Company’s SEC filings are available free of charge at www.sec.gov or upon written request to Deep Isolation Nuclear at InvestorRelations@deepisolation.com.

THE ROYALAND COMPANY LTD.

THE ROYALAND COMPANY LTD.
THE ROYALAND COMPANY LTD.

Naples, Italy and Hamilton, Bermuda, Nov. 03, 2026 (GLOBE NEWSWIRE) — The RoyaLand Company Ltd. (the “Company” or “RoyaLand”) (OTCQB: RLNDF), a Bermuda holding company focused on creating immersive, fantasy-based royalty-themed games and growing its Italian professional football club Savoia 1908 FC (“Savoia” or the “Club”), today announced a landmark moment for Savoia, which has advanced to the quarter-finals of the Coppa Italia for the first time in its 118-year history. Goals from Pasquale Riccardi and Matteo Polizzi secured a 2-0 victory over Sorrento at home on October 27, delivering a significant milestone for the Club. The Coppa Italia is an annual Italian domestic knock out competition played by 60 teams. The Copa Italia Serie C winner qualifies for the promotion playoff round for potential advancement to Serie B.

Three Matches, Three Wins

The achievement was built one round at a time. Savoia began with a 2-1 win away at Casertana on August 14, followed by a 3-0 win away at Catania on September 2, before the decisive evening against Sorrento at home. Across the three matches, the Club scored seven goals and conceded only one.

Next Up: The Defending Champs

The quarter-final brings a prestigious test: on December 8, Savoia travels to face defending champions and current cup holder Potenza. The Club views the fixture as a further source of pride and an incentive to keep improving.

October in the League

The cup success crowned a month that was also encouraging in the Serie C league. Savoia drew 0-0 away at Monopoli on October 3, defeated Inter U23 2-1 on October 10, and drew 1-1 with Cosenza on October 24, collecting valuable points along the way. The month’s only setback was a 4-0 defeat to Cerignola on October 18.


Savoia defeated Sorrento 2-0 at home.

History is Made and the Work Continues

“Reaching the quarter-finals of the Coppa Italia for the first time is an emotional moment that we share with the entire Savoia family. For 118 years, generations of supporters have cherished these colors and passed their passion down through their families. Adding a new chapter to that history fills us with pride and brings a great sense of responsibility. Credit goes to the players, the coaching staff and everyone who works on this project every day. We dedicate this historic achievement to our supporters, with the ambition of giving them even more to celebrate. October also leaves us with a positive league record. The victory over Inter U23 and the draws against Monopoli and Cosenza are important results; the defeat at Cerignola remains a match we must learn from. We are fully on track with our plan and continue to work with confidence, humility and ambition. Achieving this historic milestone gives us even greater motivation to keep moving forward.”

  • General Manager and Chief Operating Officer of Savoia, Nazario Matachione.

About The RoyaLand Company Ltd.

The RoyaLand Company Ltd. is a Bermuda holding company focused on creating an online and offline immersive, fantasy-based royalty-themed game called TheRoyal.Land as well as mobile and other games, and ownership and growth of its Italian professional football club Savoia 1908 FC. The Company’s three mobile games in development include Regalia Cards (card game), Palazzo Chronicles (match-3 castle and garden-building game) and Viva Verdi (trading card game). The Company is also actively focused on developing what it believes to be a novel, interactive and immersive game based on a player-empowered design. This game is expected to feature proprietary digital avatars and provide opportunities to players to earn in-game reward currency, build virtual land, and own their online assets while enhancing all of these features with premium incremental in-game content. Bridging the virtual video game world and terrestrial soccer, Savoia 1908 FC has also completed a tournament season for its eSports team competing in EA Sports FC™ online matches.

TheRoyal.Land and the management and development of Savoia 1908 FC are being conducted in collaboration with the Company’s founder and CEO Prince Emanuele Filiberto di Savoia — the grandson of the last King of Italy — as well as seven other royal families and families with legal, hereditary or historically based claims to royal positions in Russia, Albania, France, Bulgaria, Yugoslavia, Lesotho (Africa), and Mecklenburg (Germany). TheRoyal.Land is intended to integrate these families’ first-hand historical perspectives to deliver an authentic and unique past-meets-future entertainment experience.

CONTACT:
investors@theroyal.land
www.TheRoyal.Land

Attachment

  • CETLAM sponsors this Phase Ib pilot study in European patients with newly diagnosed AML in subpopulations with poor responses to standard-of-care treatment. Thirteen hospitals will participate
  • CETLAM is a Spanish cooperative clinical research group bringing together specialists from leading hospitals dedicated to advancing treatment research in acute leukemias and myelodysplastic syndromes
  • This additional clinical study complements Oryzon’s planned ALICE-3 Phase III program in the U.S., and will provide operational experience relevant to the program’s future European arm

MADRID and CAMBRIDGE, Mass., Nov. 03, 2026 (GLOBE NEWSWIRE) — Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and global leader in epigenetics, today announced that VIVALDI, a Phase Ib pilot study sponsored by CETLAM — Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplásicas, has been authorized in Spain. The study will evaluate iadademstat in combination with azacitidine and venetoclax in patients with newly diagnosed acute myeloid leukemia (ND-AML) belonging to subgroups associated with suboptimal responses to current standard-of-care treatment.

CETLAM is a Spanish cooperative clinical research group that brings together specialists from leading hospitals in the research and treatment of acute myeloid leukemia and myelodysplastic syndromes. The group has more than three decades of experience in developing treatment protocols and conducting collaborative clinical research. Oryzon is collaborating with CETLAM and supplying iadademstat for the study.

“VIVALDI expands our clinical investigation of iadademstat in AML in Spain through our collaboration with CETLAM’s prestigious hematology network. In parallel, we are advancing preparations for ALICE-3, our registrational Phase III trial, building on the strong clinical data from ALICE-2 to be presented soon at ASH,” said Carlos Buesa, Chief Executive Officer of Oryzon.

“Our development strategy prioritizes patients with substantial unmet need, including those with TP53 or RAS pathway mutations,” Buesa added. “VIVALDI findings in these populations may also provide complementary insights to inform future regulatory discussions. The study will also help us plan the future European arm of ALICE-3, taking into account the operational differences between conducting the trial in Europe and the United States.”

Dr. Jordi Esteve, President of CETLAM’s Board and Principal Investigator of VIVALDI at Hospital Clínic de Barcelona, said: “We are excited to bring, for the first time, this promising investigational combination to Spanish patients with TP53-mutated AML and other adverse-risk forms of the disease, building on the encouraging early clinical results and favorable tolerability observed in the U.S. ALICE-2 study. VIVALDI will also enable correlative studies to explore the biology underlying treatment response and deepen our understanding of LSD1 inhibition in these particularly difficult-to-treat leukemias.”

Dr. Olga Salamero of Vall d’Hebron University Hospital and co-Principal Investigator in VIVALDI, added: “In the earlier ALICE-1 study, led by our Vall d’Hebron University Hospital/VHIO AML team, iadademstat combined with azacitidine showed encouraging activity, including in patients with particularly poor prognoses, as the TP53+ patients where we saw a remarkable improvement in overall survival. Those findings, published in The Lancet Haematology, together with the emerging ALICE-2 results with the triplet combination, provide a strong scientific rationale for continued investigation through VIVALDI.”

Oryzon is preparing ALICE-3 as a potentially registrational Phase III study of iadademstat in combination with venetoclax and azacitidine in first-line AML, with initiation planned in 2027, subject to regulatory agreement and financing. The Company expects to present final ALICE-2 data at the 2026 American Society of Hematology (ASH) Annual Meeting. The final design of ALICE-3 remains subject to regulatory discussions and review of emerging clinical evidence.

Public information on VIVALDI is available in the Clinical Trials Information System (CTIS) under EU trial number 2026-527464-32-00.

About Oryzon
Founded in 2000 and headquartered in Barcelona, Spain, Oryzon (ISIN: ES0167733015) is a clinical-stage biopharmaceutical company and a European leader in epigenetics, with a strong focus on personalized medicine for central nervous system (CNS) disorders and oncology. Oryzon’s team comprises highly experienced pharmaceutical professionals based in Barcelona, Boston, and New Jersey. The Company has an advanced clinical portfolio built around two LSD1 inhibitors: iadademstat, its oncology/hematology program, which is being evaluated in several ongoing Phase I and II studies and has demonstrated strong preliminary clinical activity in acute myeloid leukemia (AML), including a 100% overall response rate (ORR) in first-line AML; and vafidemstat, its lead CNS program, which is Phase III–ready in borderline personality disorder (BPD) and in a Phase IIb study in schizophrenia. In addition, Oryzon is advancing a broader epigenetics pipeline targeting other mechanisms, including HDAC6, for which the Company has nominated ORY-4001 as a clinical candidate for potential development in Charcot–Marie–Tooth disease (CMT), amyotrophic lateral sclerosis (ALS), and other neurological disorders. The Company also operates a robust platform for biomarker identification and target validation across malignant and neurological diseases. For more information, visit www.oryzon.com

About Iadademstat
Iadademstat (ORY-1001) is an oral, highly selective inhibitor of the epigenetic enzyme LSD1, with potent differentiating effect in hematologic cancers. Iadademstat has shown encouraging safety and strong clinical activity in combination with azacitidine in a Phase IIa trial in elder patients with 1L acute myeloid leukemia (AML) (ALICE trial). Iadademstat is currently being evaluated in combination with azacitidine and venetoclax in 1L AML in the ALICE-2 trial, an investigator-initiated study (IIS) led by OHSU, and in combination with gilteritinib in the company-sponsored Phase Ib FRIDA trial in relapsed/refractory FLT3-mutant AML, with highly encouraging preliminary safety and efficacy data in both trials reported at EHA-2026: 100% overall response rate (ORR) and 89% composite complete remission rate (CRc), with 78% strict CR in 1L AML, and 67% CRc in R/R FLT3-mut AML. Subject to positive final data in the ALICE-2 study, the company has announced plans to conduct a potentially registrational study in 1L AML. Additional studies in hematologic malignancies include an IIS in myelodysplastic syndrome (MDS) and National Cancer Institute (NCI)-sponsored trials in myeloproliferative neoplasms and 1L AML conducted under the Cooperative Research and Development Agreement (CRADA) between Oryzon and the NCI. Beyond hematological cancers, iadademstat is being evaluated in extensive stage small cell lung cancer (ED-SCLC) in a Phase I/II randomized trial in 1L in combination with immune checkpoint inhibition (ICI) sponsored by NCI and led by the Memorial Sloan Kettering Cancer Center, and an IIS trial in combination with ICI and radiotherapy. Oryzon has also expanded iadademstat into non-oncological hematology indications, with ongoing trials in sickle cell disease and essential thrombocythemia. Iadademstat has orphan drug designation for AML in the US and EU and for SCLC in the US.

FORWARD-LOOKING STATEMENTS  
This communication contains, or may contain, forward-looking information and statements about Oryzon, including financial projections and estimates and their underlying assumptions, statements regarding plans, objectives, and expectations with respect to future operations, capital expenditures, synergies, products and services, and statements regarding future performance. Forward-looking statements are statements that are not historical facts and are generally identified by the words “expects,” “anticipates,” “believes,” “intends,” “estimates” and similar expressions. Although Oryzon believes that the expectations reflected in such forward-looking statements are reasonable, investors and holders of Oryzon shares are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Oryzon that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include those discussed or identified in the documents sent by Oryzon to the Spanish Comisión Nacional del Mercado de Valores (CNMV), which are accessible to the public. Forward-looking statements are not guarantees of future performance and have not been reviewed by the auditors of Oryzon. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date they were made. All subsequent oral or written forward-looking statements attributable to Oryzon or any of its members, directors, officers, employees, or any persons acting on its behalf are expressly qualified in their entirety by the cautionary statement above. All forward-looking statements included herein are based on information available to Oryzon on the date hereof. Except as required by applicable law, Oryzon does not undertake any obligation to publicly update or revise any forward‐looking statements, whether as a result of new information, future events, or otherwise. This document does not constitute an offer or invitation to purchase or subscribe shares in accordance with the provisions of Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017, and/or the restated text of the Securities Market Law, approved by Law 6/2023 of 17 March, and its implementing regulations. Nothing in this document constitutes investment advice. In addition, this document does not constitute an offer of purchase, sale or exchange, nor a request for an offer of purchase, sale or exchange of securities, nor a request for any vote or approval in any jurisdiction. The shares of Oryzon Genomics, S.A. may not be offered or sold in the United States of America except pursuant to an effective registration statement under the Securities Act of 1933 or pursuant to a valid exemption from registration. 

Spain Oryzon IR & Media, Europe & US  
Patricia Cobo/Mario Cordera Emili Torrell Sandya von der Weid  
Atrevia Chief BD Officer LifeSci Advisors, LLC  
+34 91 564 07 25 
+34 673 33 97 65
+34 93 515 1313 +41 78 680 05 38  
pcobo@atrevia.com 
mcordera@atrevia.com
etorrell@oryzon.com svonderweid@lifesciadvisors.com  

PETAH-TIKVA, Israel, Nov. 03, 2026 (GLOBE NEWSWIRE) — Global-e Online Ltd. (Nasdaq: GLBE), ), the leading global e-commerce enablement platform powering the world’s most iconic brands, today announced it will report financial results for the third quarter ended September 30, 2026, before market open on Wednesday, November 18, 2026.

Global-e management will host a conference call to review its financial results and outlook.

Date: Wednesday, November 18, 2026
Time: 8:00 AM ET
United States/Canada Toll Free: +1-800-717-1738
International Toll: +1-646-307-1865
   

Please join the call 5-10 minutes prior to the scheduled start time, to avoid a delay in connecting. A live webcast will be available in the Investor Relations section of Global-e’s website at https://investors.global-e.com/news-events/events-presentations

A replay of the webcast will be available in the Investor Relations section of Global-e’s website at https://investors.global-e.com/news-events/events-presentations approximately two hours after the conclusion of the call.

About Global-e Online Ltd.

Global-e (Nasdaq: GLBE) is the world’s leading platform enabling and accelerating global, Direct-To-Consumer e-commerce. The chosen partner of over 1,500 brands and retailers across North America, EMEA and APAC, Global-e makes selling internationally as simple as selling domestically. The company enables merchants to increase the conversion of international traffic into sales by offering online shoppers in over 200 destinations worldwide a seamless, localized shopping experience. Global-e’s end-to-end e-commerce solutions combine best-in-class localization capabilities, big-data best-practice business intelligence models, streamlined international logistics and vast global e-commerce experience, enabling international shoppers to buy seamlessly online and retailers to sell to, and from, anywhere in the world. For more information, please visit: www.global-e.com.

Investor Contacts:
Alan Katz
Investor Relations
Global-e
alan.katz@global-e.com

Press Contact:
Sarah Small
Headline Media
sarah@headline.media
+1 (914) 336-4718

LA JOLLA, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) — CalciMedica, Inc. (“CalciMedica” or the “Company”) (Nasdaq: CALC), a clinical-stage biopharmaceutical company developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for serious inflammatory, immunologic, and cardiopulmonary diseases, today announced that Management will participate in a fireside chat at the Guggenheim 3rd Annual Healthcare Innovation Conference on Tuesday, November 10, 2026, at 9:30 a.m. ET.

A live webcast of the presentation can be accessed in the “IR Events and Presentations” section of CalciMedica’s IR website. A replay of the webcast will be archived on the Company’s website for 90 days.

About CalciMedica
CalciMedica is a clinical-stage biopharmaceutical company developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for serious inflammatory, immunologic, and cardiopulmonary diseases. The Company’s pipeline includes two distinct CRAC channel inhibitor compounds: zegocractin, which is formulated for intravenous administration as Auxora™, and CM5480, which is designed for chronic oral dosing. Auxora has been evaluated in more than 350 patients and is being developed for pulmonary hypertension and acute pancreatitis, including a planned Phase 1b proof-of-concept trial in PH and a planned Phase 2b trial in acute pancreatitis. CM5480 is also being developed for pulmonary hypertension, with an IND submission anticipated in mid-2027. For more information, please visit www.calcimedica.com.

Investor Relations Contact
Joyce Allaire
LifeSci Advisors, LLC
jallaire@lifesciadvisors.com

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.